Skip to main content
. 2020 Mar 28;40(5):433–447. doi: 10.1007/s40261-020-00903-9

Fig. 6.

Fig. 6

Mean plasma concentration–time profiles of 3′-exonuclease degradation products of BC 007 at the applied dose of 1900 mg